The Next Generation Immunodiagnostics Company

Singulex’s proprietary Single Molecule Counting technology is the future of Next Generation Immunodiagnostics.

Learn More

Clinical Lab Testing Services
Clinical Diagnostics System

Singulex’s proprietary Single Molecule Counting technology is the backbone of next generation immunodiagnostics (NGI), which provide unprecedented ultra-sensitivity and broader dynamic range in the precision measurement of biomarkers. Such unprecedented reliable accuracy provides definitive health status answers for physicians and patients resulting in improved health outcomes and reduced healthcare costs, without reducing delivery of care. Powered by SMCTM technology, the company's NGI commercial offerings are transforming patient care from reactive disease treatment to proactive health management.


Press Releases

  • November 12, 2015
    US Patent Awarded to Singulex for Expanded Use of Biomarkers Troponin I and T to Detect Cardiac Health Status with Single-Molecule Methods
    More
  • November 5, 2015
    Singulex Receives European Patent Expanding Use of Biomarkers Troponin I and T to Detect Cardiac Health Status with High-Sensitivity Methods
    More

Upcoming Events